Inhaled drug delivery is also termed as pulmonary drug delivery. It is the inhalation of drug formulation through the mouth and further deposition of the inhaled pharmacological agent in lower airways is the main purpose of this drug delivery rate. The inhalation therapies involved the use of leaves from plants, vapours from aromatic plants, balsams and myhrr. Delivery of drugs directly to the site of action reduces the dose needed to produce a pharmacological effect.
In recent years, the possibility of utilizing the pulmonary route for the systemic delivery of peptides and other molecules that are not absorbed through the gastrointestinal tract has also been explored.
Important Alert:
X
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Photodegradation of two pharmaceutical namely levofloxacin and atorvastatin via Chitosan/Ag/TiO2 3D printed scaffold
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, Mansfield Bioincubator, United States
Title : Unveiling the binding interactions of selected antimalarial drugs with major plasma transporter
Saad Tayyab, UCSI University, Malaysia
Title : Pharmacokinetic properties of TNX-102 SL, a sublingual formulation of cyclobenzaprine hydrochloride
Bruce Daugherty, Tonix Pharmaceuticals, United States
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Mannitol as eutectic forming agent for improved sublingual delivery of Cyclobenzaprine HCl
Marino Nebuloni, University of Insubria, Italy